Henry Schein, Inc. (NASDAQ:HSIC) Given Average Rating of “Hold” by Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have been given a consensus recommendation of “Hold” by the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $92.2667.

HSIC has been the topic of a number of research reports. Robert W. Baird set a $97.00 target price on shares of Henry Schein in a research report on Wednesday, May 6th. Citigroup restated a “buy” rating and issued a $112.00 price target (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. UBS Group set a $94.00 price objective on shares of Henry Schein and gave the company a “neutral” rating in a report on Wednesday, August 5th. BTIG Research reissued a “buy” rating and set a $100.00 price objective on shares of Henry Schein in a research report on Wednesday, August 5th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Henry Schein in a research note on Friday, July 31st.

Institutional Investors Weigh In On Henry Schein

A number of hedge funds have recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein during the second quarter valued at approximately $25,000. MUFG Securities EMEA plc bought a new position in shares of Henry Schein in the 2nd quarter worth $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein in the 4th quarter valued at $30,000. Federated Hermes Inc. acquired a new stake in Henry Schein in the 4th quarter valued at $32,000. Finally, Los Angeles Capital Management LLC bought a new stake in Henry Schein during the 4th quarter valued at $37,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Trading Down 0.7%

NASDAQ HSIC opened at $90.12 on Friday. The business has a 50 day simple moving average of $84.56 and a 200 day simple moving average of $78.98. Henry Schein has a one year low of $61.94 and a one year high of $92.18. The stock has a market capitalization of $10.04 billion, a P/E ratio of 26.27, a P/E/G ratio of 1.73 and a beta of 0.80. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.32 and a quick ratio of 0.73.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. The business had revenue of $3.46 billion during the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Research analysts expect that Henry Schein will post 5.35 earnings per share for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.